Enhanced Rates and Magnitude of Immune Responses Detected against an HIV Vaccine: Effect of Using an Optimized Process for Isolating PBMC
- 1 January 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 23 (1) , 86-92
- https://doi.org/10.1089/aid.2006.0129
Abstract
Quantitative analysis of cell-mediated immune responses induced by candidate HIV vaccines requires robust procedures for collecting and processing human peripheral mononuclear blood cells (PBMCs). We evaluated several parameters in order to optimize a sample handling process that would be suitable for a multicenter clinical trial. Among the findings, systematic increases in the magnitude of IFN-gamma ELISpot responses were observed when the time from blood collection to PBMC freezing was reduced to <12 h. By implementing these improvements within an ongoing clinical trial, the estimated immunologic response rates to an adenovirus- based HIV vaccine increased by more than 20 percentage points to approximately 80% of the vaccine recipients against any of the vaccine antigens and the average levels of T cell response improved more than 3-fold. These studies establish the importance of optimal conditions for PBMC collection and handling to the success of a clinical development program.Keywords
This publication has 20 references indexed in Scilit:
- T cell vaccines for microbial infectionsNature Medicine, 2005
- Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative studyStatistics in Medicine, 2004
- Intracellular Staining for HIV-Specific IFN-γ Production: Statistical Analyses Establish Reproducibility and Criteria for Distinguishing Positive ResponsesJournal of Interferon & Cytokine Research, 2003
- Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag GeneJournal of Virology, 2003
- Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-? ELISPOT assay: Responses in an elderly population receiving a booster immunizationJournal of Medical Virology, 2003
- Moving to Human Immunodeficiency Virus Type 1 Vaccine Efficacy Trials: Defining T Cell Responses As Potential Correlates of ImmunityThe Journal of Infectious Diseases, 2003
- Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature, 2002
- Accessing Complexity: The Dynamics of Virus-Specific T Cell ResponsesAnnual Review of Immunology, 2000
- Parameters Influencing Measurement of the Gag Antigen-Specific T-Proliferative Response to HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2000
- Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + LymphocytesScience, 1999